Detalles de la búsqueda
1.
Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement.
Lancet Oncol
; 24(10): e415-e423, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37797647
2.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
N Engl J Med
; 382(7): 610-621, 2020 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31825192
3.
BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study.
J Genet Couns
; 30(2): 383-393, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33010199
4.
Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study.
Cancer
; 126(6): 1183-1192, 2020 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31860135
5.
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer.
Support Care Cancer
; 28(2): 925-932, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31172284
6.
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Breast Cancer Res
; 21(1): 39, 2019 03 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30867034
7.
Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotype.
Cancer
; 125(24): 4516-4524, 2019 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31553501
8.
When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab.
Curr Oncol Rep
; 21(12): 109, 2019 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31781874
9.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(12): 1688-1700, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29146401
10.
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
Breast Cancer Res
; 19(1): 18, 2017 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28183331
11.
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices.
J Natl Compr Canc Netw
; 13(11): 1383-93, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26553767
12.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Nat Commun
; 15(1): 2691, 2024 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38538574
13.
Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States.
Drugs Real World Outcomes
; 10(2): 177-186, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36539672
14.
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.
NPJ Precis Oncol
; 7(1): 18, 2023 Feb 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36797347
15.
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Eur J Cancer
; 184: 48-59, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898233
16.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
medRxiv
; 2023 Dec 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38105958
17.
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
JAMA Oncol
; 8(8): 1190-1194, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35653145
18.
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
J Clin Oncol
; 39(13): 1485-1505, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33507815
19.
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.
J Clin Oncol
; 39(24): 2720-2731, 2021 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34003702
20.
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.
J Clin Oncol
; 39(6): 685-693, 2021 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33079579